Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

a2 Milk Slides on the ASX as China Recovery Faces a Crucial Test

a2 Milk Slides on the ASX as China Recovery Faces a Crucial Test Source: Kapitales Research

Highlights

  • China-label formula purchases have recovered to about half their level before the supply disruption.
  • Management expects FY27 formula sales to remain broadly flat despite new product launches.
  • The company forecasts an underlying EBITDA margin of about 15%, with a weaker first half.

Shares in The a2 Milk Company Limited (ASX: A2M) fell 8.4% to AU$6.640 on 19 November 2026 as the company updated its outlook at its annual meeting. Management expects group revenue and EBITDA to grow this financial year, with much of that performance concentrated in the second half as it works to win back formula buyers in China.

China’s recovery is still uneven

The company estimated that consumer purchases of its China-label infant formula had recovered to around 50% of pre-disruption levels, up from around 40% in August. Fourth-quarter shortages pushed many families to rival brands. Online market share rose to 2.5% in the first quarter from 1.8% in the previous quarter, while share in mother-and-baby stores held at 2.1%, according to the company.

Two new China-label formulas and an updated a2 Platinum are part of the recovery plan. China’s import requirements still constrain a2 Genesis sales. Management expects total infant formula sales to remain broadly flat in FY27.

Revenue rose, but reported profit fell

On a continuing operations basis, the company reported FY26 revenue of NZ$1,974.90 million, up 12.4%. Reported EBITDA fell 2.5% to NZ$284.40 million, while net profit fell 5.8% to NZ$207.50 million. Underlying EBITDA rose 5.4% to NZ$307.60 million at a 15.6% margin, while underlying net profit rose 7.0% to NZ$235.80 million.

Reported EBITDA margin fell to 14.4%. Basic earnings per share declined 6.0% to 28.60 NZ cents, while underlying earnings per share climbed 6.8% to 32.50 NZ cents.

Cash stood at NZ$784.50 million, with 68% cash conversion. Ordinary dividends totalled 21.00 NZ cents per share, representing a 74% payout ratio. The company also declared a NZ$300.00 million special dividend.

Outlook

First-half revenue is expected to dip slightly and the underlying margin to fall materially year on year. The margin guidance excludes about NZ$15.00 million in one-off a2 Pōkeno transformation costs. Liquid milk, other nutritional products and new markets are expected to support growth.

The company expects cash conversion of 70% to 80%, capital expenditure of about NZ$70.00 million and depreciation and amortisation of about NZ$20.00 million. Management expects revenue to reach its NZ$2.00 billion goal in FY27. For shareholders, the next test is whether gains in online market share translate into a broader recovery in China.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au